Baxter International Inc vs Mesoblast Limited — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Baxter International Inc is far larger — about 6.6× Mesoblast Limited's market cap, and Baxter International Inc pays a 0.14% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BAX | MESO | |
|---|---|---|
Market Cap | $14.36B | $2.16B |
Sector | Health | Technology |
52-Week High | $28.35 | $20.96 |
52-Week Low | $15.80 | $12.88 |
Enterprise Value | $21.88B | $2.17B |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →